Congenital hyperinsulinism (CHI) is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent occurrences of low blood sugar (hypoglycemia). In infants and young children, these occurrences are characterized by a lack of energy (lethargy), irritability, or difficulty feeding. Repeated episodes of low blood sugar increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma.
The severity of CHI varies widely among affected individuals, even among members of the same family. About 60% of infants with this condition experience a hypoglycemic episode within the first month of life. Other affected children develop hypoglycemia by early childhood. Unlike typical episodes of hypoglycemia, which occur most often after periods without food (fasting) or after exercising, episodes of hypoglycemia in people with CHI can also occur after eating.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-market
The Congenital Hyperinsulinism market report also covers emerging drugs, current treatment practices, Congenital Hyperinsulinism market share of the individual therapies, current and forecasted Congenital Hyperinsulinism Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Congenital Hyperinsulinism treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Congenital Hyperinsulinism Market Key Facts
According to the National Institute of Health, CHI affects approximately 1 in 50,000 newborns. This condition is more common in certain populations, affecting up to 1 in 2,500 newborns.
The total prevalent population of CHI in the 7 major markets was estimated to be 21,852 cases in 2017, which is expected to increase by 2030.
Among the EU5 countries, Germany had the highest prevalent population of CHI with 2,374 cases in 2017, followed by the UK and France. On the other hand, Spain had the lowest prevalent Population.
In 2017, the total prevalent population of CHI in the United States was found to be 9,777.
Key Benefits of Congenital Hyperinsulinism Market Report
-
Congenital Hyperinsulinism market report provides an in-depth analysis of Congenital Hyperinsulinism Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Congenital Hyperinsulinism market report will help in developing business strategies by understanding the Congenital Hyperinsulinism Market trends & developments, key players and future market competition that will shape and drive the Congenital Hyperinsulinism market in the upcoming years.
-
The Congenital Hyperinsulinism market report covers Congenital Hyperinsulinism current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Congenital Hyperinsulinism market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Congenital Hyperinsulinism Market
The Congenital Hyperinsulinism market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Congenital Hyperinsulinism market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Congenital Hyperinsulinism market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Congenital Hyperinsulinism Epidemiology
The Congenital Hyperinsulinism epidemiology section covers insights about historical and current Congenital Hyperinsulinism patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Congenital Hyperinsulinism Drugs Uptake and Key Market Players
The Congenital Hyperinsulinism Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Congenital Hyperinsulinism market or expected to get launched in the market during the study period. The analysis covers Congenital Hyperinsulinism market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The key players in Congenital Hyperinsulinism market include
Zealand Pharma
Rezolute
Xeris Pharmaceuticals
Eiger BioPharmaceuticals
AmideBio
Recordati
Teva Pharmaceuticals
And others.
Table of Content
1. Key Insights
2. Executive Summary
3. Congenital Hyperinsulinism Competitive Intelligence Analysis
4. Congenital Hyperinsulinism Market Overview at a Glance
5. Congenital Hyperinsulinism Disease Background and Overview
6. Congenital Hyperinsulinism Patient Journey
7. Congenital Hyperinsulinism Epidemiology and Patient Population
8. Congenital Hyperinsulinism Treatment Algorithm, Current Treatment, and Medical Practices
9. Congenital Hyperinsulinism Unmet Needs
10. Key Endpoints of Congenital Hyperinsulinism Treatment
11. Congenital Hyperinsulinism Marketed Products
12. Congenital Hyperinsulinism Emerging Therapies
13. Congenital Hyperinsulinism Seven Major Market Analysis
14. Attribute Analysis
15. Congenital Hyperinsulinism Market Outlook (7 major markets)
16. Congenital Hyperinsulinism Access and Reimbursement Overview
17. KOL Views on the Congenital Hyperinsulinism Market.
18. Congenital Hyperinsulinism Market Drivers
19. Congenital Hyperinsulinism Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Related Reports
Congenital Hyperinsulinism Pipeline Insights, 2020
Congenital Hyperinsulinism Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Congenital Hyperinsulinism market.
Congenital Hyperinsulinism Epidemiology Forecast to 2030
DelveInsight’s Congenital Hyperinsulinism – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Congenital Hyperinsulinism in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/